ArticleGut pathogens2025
Acute gastroenteritis due to Arcobacter butzleri: an emerging pathogen.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arcobacter butzleri is a foodborne pathogen that has been positioned as an emerging cause of bacterial enteritis. It can affect any type of person although vulnerable people are more susceptible. In addition, resistance to several antibiotics has been described, which is a problem for antimicrobial empirical treatment and this makes it a threat to public health.Seven isolates of this pathogen were collected during 2024. Susceptibility studies were performed on first-line antibiotics for the treatment of gastroenteritis in our epidemiological environment. Resistance rates higher than 25% were observed for all antimicrobials tested, except erythromycin. Based on these data, it would be necessary to carry out a study of antimicrobial resistance profile of this microorganism for their treatment and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.